Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
The Lancet. Haematology|March 5, 2017
Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trialJeffrey A Jones, Tadeusz Robak, Jennifer R Brown, et al.
Haematologica|October 14, 2011
Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemiaHarry Iland, Ken Bradstock, John Seymour, et al.
Blood|October 31, 2002
Granulocyte-colony stimulating factor increases CD123hi blood dendritic cells with altered CD62L and CCR7 expressionSlavica Vuckovic, Min Kim, Dailal Khalil, et al.
Blood Advances|May 13, 2024
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16Peter Mollee, John Reynolds, Wojt Janowski, et al.
Blood|June 21, 2012
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)Harry J Iland, Ken Bradstock, Shane G Supple, et al.
The Lancet. Haematology|December 22, 2015
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trialHarry J Iland, Marnie Collins, Ken Bradstock, et al.
Blood|June 24, 2004
A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabineKenneth F Bradstock, Jane P Matthews, Raymond M Lowenthal, et al.
Blood|September 5, 2008
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapyTimothy P Hughes, Susan Branford, Deborah L White, et al.
The Journal of Rheumatology|March 3, 2004
Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTRJohn A Snowden, Jakob Passweg, John J Moore, et al.
The New England Journal of Medicine|March 15, 2003
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaStephen G O'Brien, François Guilhot, Richard A Larson, et al.
Pageof 8